HIMS CEO Form 4: 108,334 and 17,001 options exercised; sales filed
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Hims & Hers Health (HIMS) CEO and 10% owner Andrew Dudum reported multiple insider transactions on 10/16/2025 under a Rule 10b5-1 plan adopted on August 28, 2024. He exercised stock options at an exercise price of $2.43 and sold shares in several tranches at weighted average prices disclosed within ranges, including $62.50–$62.87, $62.215–$63.13, and $63.31–$63.59.
Reported option exercises included 108,334 and 17,001 shares, followed by sales such as 39,531, 39,332, 39,111, 17,001, and smaller lots. After the transactions, reported direct holdings included 109,190 shares, with additional indirect holdings across multiple family trusts, each listed with its own balance.
Positive
- None.
Negative
- None.
Insights
Routine Form 4 under a pre-set 10b5-1 plan.
The CEO executed option exercises at an exercise price of $2.43 and sold shares in multiple trades on 10/16/2025. The filing states the activity was effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024, indicating pre-arranged instructions.
Weighted-average sale prices are provided in ranges (e.g., $62.50–$62.87 and $63.31–$63.59) with an undertaking to furnish full breakdowns upon request. This is standard disclosure and does not indicate issuer cash inflow.
Post-transaction, direct holdings are reported alongside multiple indirect trust holdings. Market impact depends on trade size relative to daily volume; actual effects will be determined by market conditions.
Insider Trade Summary
Net Seller: 175,661 shares ($11,029,999)
Net Sell
20 txns
Insider
Dudum Andrew
Role
Chief Executive Officer
Sold
175,661 shs ($11.03M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 17,001 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 108,334 | $0.00 | -- |
| Sale | Class A Common Stock | 2,792 | $62.6518 | $175K |
| Sale | Class A Common Stock | 39,111 | $62.6997 | $2.45M |
| Sale | Class A Common Stock | 8,423 | $63.4588 | $535K |
| Exercise | Class A Common Stock | 17,001 | $2.43 | $41K |
| Sale | Class A Common Stock | 17,001 | $62.69 | $1.07M |
| Exercise | Class A Common Stock | 108,334 | $2.43 | $263K |
| Sale | Class A Common Stock | 39,531 | $62.7053 | $2.48M |
| Sale | Class A Common Stock | 10,469 | $63.4852 | $665K |
| Sale | Class A Common Stock | 39,332 | $62.6999 | $2.47M |
| Sale | Class A Common Stock | 2,335 | $63.3873 | $148K |
| Sale | Class A Common Stock | 16,667 | $62.6969 | $1.04M |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 17,005 shares (Direct);
Class A Common Stock — 92,523 shares (Direct);
Class A Common Stock — 55,947 shares (Indirect, Held by Trustee of Dudum Family Community Property Trust)
Footnotes (1)
- The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.50 - $62.87. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.215 - $63.13. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.31 - $63.59. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.25 - $62.94. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.22 - $63.18. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.25 - $63.63. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.22 - $63.20. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.26 - $63.47. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Prior to the Company's business combination transaction in 2021, the option represented the right to purchase 7,166,182 shares of Hims, Inc. with an exercise price of $1.10. Following the Company's business combination transaction in 2021, the option converted into the right to purchase 3,246,139 shares of the Company with an exercise price of $2.43. 100% of the shares subject to the option vested upon certain specified thresholds met in 2021. The Stock Option was received in exchange for an option to purchase 3,583,091 shares of Class A Common Stock of Hims, Inc., with an exercise price of $1.10, in connection with the Merger. 1/48 of the shares subject to the Stock Option vest when the Reporting Person completes each month of continuous Service beginning March 13, 2020.
FAQ
What did HIMS CEO Andrew Dudum report on Form 4?
He exercised stock options at an exercise price of $2.43 and sold shares in multiple tranches on 10/16/2025 under a Rule 10b5-1 plan.
Were the HIMS insider sales under a 10b5-1 plan?
Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.
What price ranges did the HIMS insider sales occur at?
Weighted-average sale prices were disclosed in ranges including $62.50–$62.87, $62.215–$63.13, and $63.31–$63.59.
How many HIMS options were exercised by the CEO?
Reported exercises included 108,334 and 17,001 shares at an exercise price of $2.43.
What are the CEO’s reported direct HIMS holdings after the transactions?
The filing shows 109,190 shares held directly after the reported transactions.
Did the CEO have indirect HIMS holdings?
Yes. The filing lists multiple indirect holdings across family trusts, each reported with its own share balance.